Page last updated: 2024-09-03

cyclo(prolylglycyl) and piracetam

cyclo(prolylglycyl) has been researched along with piracetam in 3 studies

Compound Research Comparison

Studies
(cyclo(prolylglycyl))
Trials
(cyclo(prolylglycyl))
Recent Studies (post-2010)
(cyclo(prolylglycyl))
Studies
(piracetam)
Trials
(piracetam)
Recent Studies (post-2010) (piracetam)
480283,3455571,169

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gudasheva, TA; Ostrovskaia, RU; Seredenin, SB; Skoldinov, AP; Trofimov, SS; Voronina, TA1
Antipov, TA; Gudasheva, TA; Kolisnikova, KN; Nazarova, GA; Seredenin, SB; Voronina, TA1
Antipova, TA; Gudasheva, TA; Koliasnikova, KN; Seredenin, SB1

Other Studies

3 other study(ies) available for cyclo(prolylglycyl) and piracetam

ArticleYear
[Novel endogenous dipeptide cycloprolyl-glycine is similar to pyracetam in selectivity of their mnemotropic effect].
    Biulleten' eksperimental'noi biologii i meditsiny, 1999, Volume: 128, Issue:10

    Topics: Animals; Avoidance Learning; Conditioning, Psychological; Dipeptides; Glycine; Male; Memory; Nootropic Agents; Peptides, Cyclic; Piracetam; Rats

1999
[Similarity of cycloprolylglycine to piracetam in antihypoxic and neuroprotective effects].
    Eksperimental'naia i klinicheskaia farmakologiia, 2012, Volume: 75, Issue:9

    Topics: Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Hypercapnia; Hypoxia; Mice; Mice, Inbred BALB C; Neuroprotective Agents; Oxidopamine; Peptides, Cyclic; Piracetam; Sympatholytics

2012
Neuropeptide cycloprolylglycine increases the levels of brain-derived neurotrophic factor in neuronal cells.
    Doklady. Biochemistry and biophysics, 2016, Volume: 469, Issue:1

    Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Line; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glutamic Acid; Hippocampus; Humans; Mice; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Peptides, Cyclic; Piracetam

2016